UBS Group’s NeuroMetrix, Inc. Common Stock NURO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,889
| Closed | -$8.35K | – | 11225 |
|
|
2025
Q1 | $8.35K | Sell |
1,889
-263
| -12% | -$1.13K | ﹤0.01% | 8765 |
|
|
2024
Q4 | $8.54K | Buy |
2,152
+694
| +48% | +$2.81K | ﹤0.01% | 8405 |
|
|
2024
Q3 | $5.79K | Buy |
+1,458
| New | +$5.35K | ﹤0.01% | 8028 |
|
|
2024
Q2 | – | Sell |
-2,156
| Closed | -$9.16K | – | 10382 |
|
|
2024
Q1 | $9.16K | Buy |
2,156
+2,042
| +1,791% | +$7.1K | ﹤0.01% | 7295 |
|
|
2023
Q4 | $410 | Buy |
+114
| New | +$479 | ﹤0.01% | 8675 |
|
|
2023
Q3 | – | Sell |
-90
| Closed | -$705 | – | 10159 |
|
|
2023
Q2 | $705 | Sell |
90
-408
| -82% | -$3.77K | ﹤0.01% | 8124 |
|
|
2023
Q1 | $5.86K | Buy |
+498
| New | +$6.75K | ﹤0.01% | 7979 |
|
|
2022
Q4 | – | Sell |
-415
| Closed | -$9K | – | 11345 |
|
|
2022
Q3 | $9K | Buy |
415
+363
| +698% | +$9.96K | ﹤0.01% | 8623 |
|
|
2022
Q2 | $1K | Buy |
52
+23
| +79% | +$687 | ﹤0.01% | 10047 |
|
|
2022
Q1 | $1K | Sell |
29
-27
| -48% | -$960 | ﹤0.01% | 9985 |
|
|
2021
Q4 | $2K | Sell |
56
-79
| -59% | -$4.67K | ﹤0.01% | 9860 |
|
|
2021
Q3 | $11K | Sell |
135
-859
| -86% | -$76.9K | ﹤0.01% | 7919 |
|
|
2021
Q2 | $27K | Buy |
994
+900
| +957% | +$23.1K | ﹤0.01% | 7051 |
|
|
2021
Q1 | $3K | Sell |
94
-217
| -70% | -$6.58K | ﹤0.01% | 8545 |
|
|
2020
Q4 | $8K | Sell |
311
-411
| -57% | -$6.75K | ﹤0.01% | 7644 |
|
|
2020
Q3 | $10K | Buy |
+722
| New | +$10.9K | ﹤0.01% | 6876 |
|
|
2020
Q1 | – | Sell |
-220
| Closed | -$8K | – | 8534 |
|
|
2019
Q4 | $8K | Sell |
220
-155
| -41% | -$4.49K | ﹤0.01% | 7409 |
|
|
2019
Q3 | $10K | Buy |
375
+172
| +85% | +$5.19K | ﹤0.01% | 7181 |
|
|
2019
Q2 | $7K | Buy |
+203
| New | +$11.9K | ﹤0.01% | 7260 |
|
|
2019
Q1 | – | Sell |
-25
| Closed | -$1K | – | 8288 |
|
|
2018
Q4 | $1K | Buy |
25
+13
| +108% | +$1.08K | ﹤0.01% | 7929 |
|
|
2018
Q3 | $1K | Sell |
12
-10
| -45% | -$1.01K | ﹤0.01% | 7865 |
|
|
2018
Q2 | $2K | Sell |
22
-43
| -66% | -$4.74K | ﹤0.01% | 7749 |
|
|
2018
Q1 | $7K | Buy |
65
+37
| +132% | +$4.64K | ﹤0.01% | 7093 |
|
|
2017
Q4 | $4K | Buy |
28
+22
| +367% | +$3.16K | ﹤0.01% | 7481 |
|
|
2017
Q3 | $1K | Buy |
+6
| New | +$988 | ﹤0.01% | 7604 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 8069 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 8073 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 8112 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | -$1K | – | 8316 |
|
|
2015
Q4 | $1K | Buy |
+1
| New | +$1.78K | ﹤0.01% | 8186 |
|
|
2015
Q3 | – | Sell |
-3
| Closed | -$7K | – | 8705 |
|
|
2015
Q2 | $7K | Buy |
3
+1
| +50% | +$3K | ﹤0.01% | 7718 |
|
|
2015
Q1 | $9K | Buy |
2
+1
| +100% | +$4.4K | ﹤0.01% | 7741 |
|
|
2014
Q4 | $6K | Buy |
+1
| New | +$4.38K | ﹤0.01% | 8869 |
|
UBS Group's NURO Position: Q2 2025 in Review
UBS Group sold out of NeuroMetrix, Inc. Common Stock (NURO) in Q2 2025, closing a stake of 1,889 shares — an estimated $8.35K sold.
UBS Group first reported a position in NURO in Q4 2014 and held it in 29 quarters. The position peaked at $27K in Q2 2021. 0 funds tracked by Wall St. Rank hold NURO as of Q2 2025.
- UBS Group reported no remaining NeuroMetrix, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 1,889 NeuroMetrix, Inc. Common Stock shares in Q2 2025, an estimated $8.35K.
- UBS Group first reported a position in NeuroMetrix, Inc. Common Stock in Q4 2014 and held it in 29 quarters.
- UBS Group's NeuroMetrix, Inc. Common Stock position peaked at $27K in Q2 2021.
- 0 funds tracked by Wall St. Rank held NeuroMetrix, Inc. Common Stock as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.